Lineage Cell Therapeutics, Inc.
LCTX
$0.5111
$0.02555.25%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -47.63% | -24.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -47.63% | -24.11% | |||
| Cost of Revenue | -16.66% | 11.47% | |||
| Gross Profit | -108.60% | -224.39% | |||
| SG&A Expenses | 10.36% | -0.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.36% | 4.71% | |||
| Operating Income | -27.30% | -33.07% | |||
| Income Before Tax | -27.48% | -8.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -27.48% | -8.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 117.39% | 30.30% | |||
| Net Income | -26.46% | -7.88% | |||
| EBIT | -27.30% | -33.07% | |||
| EBITDA | -27.87% | -34.06% | |||
| EPS Basic | -34.56% | 15.53% | |||
| Normalized Basic EPS | -32.56% | 14.85% | |||
| EPS Diluted | -34.56% | 15.53% | |||
| Normalized Diluted EPS | -32.56% | 14.85% | |||
| Average Basic Shares Outstanding | -5.89% | 27.20% | |||
| Average Diluted Shares Outstanding | -5.89% | 27.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||